Pembrolizumab is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is used to treat advanced skin cancer (melanoma) that has spread to other parts of the body. It is also used to treat a certain type of non-small cell lung cancer, if your tumor has a specific genetic marker for which your doctor will test. Keytruda Pembrolizumab is also used to treat head and neck cancer that has spread to other parts of the body, or has come back after prior treatment. Pembrolizumab is also used to treat Hodgkin lymphoma in adults and children.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Some side effects may occur during the injection. Tell your doctor right away if you feel dizzy, light-headed, itchy, hot or cold, sweaty, tingly, feverish, or if you have trouble breathing.
Keytruda is classified as a monoclonal antibody. Monoclonal antibodies are a relatively new type of “targeted” cancer therapy. Antibodies are an integral part of the body’s immune system. Normally, the body creates antibodies in response to an antigen (such as a protein in a germ) that has entered the body. The antibodies attach to the antigen in order to mark it for destruction by the immune system.